Literature DB >> 17202306

Intranasal coadministration of live lactococci producing interleukin-12 and a major cow's milk allergen inhibits allergic reaction in mice.

Naima G Cortes-Perez1, Sandrine Ah-Leung, Luis G Bermúdez-Humarán, Gérard Corthier, Jean-Michel Wal, Philippe Langella, Karine Adel-Patient.   

Abstract

The Th1/Th2 balance deregulation toward a Th2 immune response plays a central role in allergy. We previously demonstrated that administration of recombinant Lactococcus lactis strains expressing bovine beta-lactoglobulin (BLG), a major cow's milk allergen, partially prevents mice from sensitization. In the present study, we aimed to improve this preventive effect by coadministration of L. lactis BLG and a second recombinant L. lactis strain producing biologically active interleukin-12 (IL-12). This L. lactis strain producing IL-12 was previously used to enhance the Th1 immune response in a tumoral murine model (L. G. Bermúdez-Humarán et al., J. Immunol. 175:7297-7302, 2005). A comparison of the administration of either BLG alone or BLG in the presence of IL-12 was conducted. A BLG-specific primary Th1 immune response was observed only after intranasal coadministration of both L. lactis BLG and IL-12-producing L. lactis, as demonstrated by the induction of serum-specific immunoglobulin G2a (IgG2a) concomitant with gamma interferon secretion by splenocytes, confirming the adjuvanticity of IL-12-producing L. lactis. Immunized mice were further sensitized by intraperitoneal administration of purified BLG, and the allergic reaction was elicited by intranasal challenge with purified BLG. Mice pretreated with BLG in either the presence or the absence of IL-12 were rendered completely tolerant to further allergic sensitization and elicitation. Pretreatment with either L. lactis BLG or L. lactis BLG and IL-12-producing L. lactis induces specific anti-BLG IgG2a production in serum and bronchoalveolar lavage (BAL) fluid. Although specific serum IgE was not affected by these pretreatments, the levels of eosinophilia and IL-5 secretion in BAL fluid were significantly reduced after BLG challenge in the groups pretreated with L. lactis BLG and L. lactis BLG-IL-12-producing L. lactis, demonstrating a decreased allergic reaction. Our data demonstrate for the first time (i) the induction of a protective Th1 response by the association of L. lactis BLG and IL-12-producing L. lactis which inhibits the elicitation of the allergic reaction to BLG in mice and (ii) the efficiency of intranasal administration of BLG for the induction of tolerance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202306      PMCID: PMC1828845          DOI: 10.1128/CVI.00299-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  57 in total

1.  Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation.

Authors:  C Venkataraman; S Leung; A Salvekar; H Mano; U Schindler
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

2.  Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Authors:  J P Leonard; M L Sherman; G L Fisher; L J Buchanan; G Larsen; M B Atkins; J A Sosman; J P Dutcher; N J Vogelzang; J L Ryan
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

Review 3.  Potential and opportunities for use of recombinant lactic acid bacteria in human health.

Authors:  Sean Hanniffy; Ursula Wiedermann; Andreas Repa; Annick Mercenier; Catherine Daniel; Jean Fioramonti; Helena Tlaskolova; Hana Kozakova; Hans Israelsen; Søren Madsen; Astrid Vrang; Pascal Hols; Jean Delcour; Peter Bron; Michiel Kleerebezem; Jerry Wells
Journal:  Adv Appl Microbiol       Date:  2004       Impact factor: 5.086

Review 4.  Cytokines induce the development of functionally heterogeneous T helper cell subsets.

Authors:  A O'Garra
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

5.  Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

Authors:  R J Motzer; A Rakhit; L H Schwartz; T Olencki; T M Malone; K Sandstrom; R Nadeau; H Parmar; R Bukowski
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

Review 6.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

7.  Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.

Authors:  B P Arulanandam; M O'Toole; D W Metzger
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

8.  Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery.

Authors:  B P Arulanandam; D W Metzger
Journal:  Vaccine       Date:  1999-01-21       Impact factor: 3.641

Review 9.  Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship.

Authors:  S R Paludan
Journal:  Scand J Immunol       Date:  1998-11       Impact factor: 3.487

10.  Two-site enzyme immunometric assays for determination of native and denatured beta-lactoglobulin.

Authors:  L Negroni; H Bernard; G Clement; J M Chatel; P Brune; Y Frobert; J M Wal; J Grassi
Journal:  J Immunol Methods       Date:  1998-11-01       Impact factor: 2.303

View more
  19 in total

Review 1.  Future therapies for food allergies.

Authors:  Anna Nowak-Węgrzyn; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2011-01-31       Impact factor: 10.793

Review 2.  Nonallergen-specific treatments for food allergy.

Authors:  Jay A Lieberman; Julie Wang
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-06

Review 3.  Strategies of mucosal immunotherapy for allergic diseases.

Authors:  Yi-Ling Ye; Ya-Hui Chuang; Bor-Luen Chiang
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

4.  Maternal peanut consumption provides protection in offspring against peanut sensitization that is further enhanced when co-administered with bacterial mucosal adjuvant.

Authors:  Iván López-Expósito; Kirsi M Järvinen; Alexandra Castillo; Antti E Seppo; Ying Song; Xiu-Min Li
Journal:  Food Res Int       Date:  2011-07       Impact factor: 6.475

Review 5.  Food allergy.

Authors:  Julie Wang; Hugh A Sampson
Journal:  J Clin Invest       Date:  2011-03-01       Impact factor: 14.808

6.  Food allergy: recent advances in pathophysiology and treatment.

Authors:  Julie Wang; Hugh A Sampson
Journal:  Allergy Asthma Immunol Res       Date:  2009-09-25       Impact factor: 5.764

Review 7.  Food allergy diagnosis and therapy: where are we now?

Authors:  Aleena Syed; Arunima Kohli; Kari C Nadeau
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

Review 8.  Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.

Authors:  Luis G Bermúdez-Humarán; Pascale Kharrat; Jean-Marc Chatel; Philippe Langella
Journal:  Microb Cell Fact       Date:  2011-08-30       Impact factor: 5.328

9.  Oral Administration of Lactococcus lactis Expressing Synthetic Genes of Myelin Antigens in Decreasing Experimental Autoimmune Encephalomyelitis in Rats.

Authors:  Kaja Kasarello; Barbara Kwiatkowska-Patzer; Andrzej W Lipkowski; Jacek K Bardowski; Agnieszka K Szczepankowska
Journal:  Med Sci Monit       Date:  2015-05-31

10.  Immunomodulatory Activity of Lactococcus lactis A17 from Taiwan Fermented Cabbage in OVA-Sensitized BALB/c Mice.

Authors:  Hui-Ching Mei; Yen-Wenn Liu; Yi-Chin Chiang; Shiou-Huei Chao; Nai-Wen Mei; Yu-Wen Liu; Ying-Chieh Tsai
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-21       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.